Literature DB >> 25116100

Glycosylation and Fc receptors.

Jerrard M Hayes1, Eoin F J Cosgrave, Weston B Struwe, Mark Wormald, Gavin P Davey, Roy Jefferis, Pauline M Rudd.   

Abstract

Immunoglobulins and Fc receptors are critical glycoprotein components of the immune system. Fc receptors bind the Fc (effector) region of antibody molecules and communicate information within the innate and adaptive immune systems. Glycosylation of antibodies, particularly in the Fc region of IgG, has been extensively studied in health and disease. The N-glycans in the identical heavy chains have been shown to be critical for maintaining structural integrity, communication with the Fc receptor and the downstream immunological response. Less is known about glycosylation of the Fc receptor in either healthy or disease states, however, recent studies have implicated an active role for receptor associated oligosaccharides in the antibody-receptor interaction. Research into Fc receptor glycosylation is increasing rapidly, where Fc receptors are routinely used to analyze the binding of therapeutic monoclonal antibodies and where glycosylation of receptors expressed by cells of the immune system could potentially be used to mediate and control the differential binding of immunoglobulins. Here we discuss the glycosylation of immunoglobulin antibodies (IgA, IgE, IgG) and the Fc receptors (FcαR, FcεR, FcγR, FcRn) that bind them, the function of carbohydrates in the immune response and recent advances in our understanding of these critical glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25116100     DOI: 10.1007/978-3-319-07911-0_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  40 in total

Review 1.  Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.

Authors:  Austin Wt Chiang; Shangzhong Li; Philipp N Spahn; Anne Richelle; Chih-Chung Kuo; Mojtaba Samoudi; Nathan E Lewis
Journal:  Curr Opin Struct Biol       Date:  2016-09-14       Impact factor: 6.809

Review 2.  Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.

Authors:  Bing-Bing Yang; Sameer Doshi; Karen Arkam; Janet Franklin; Andrew T Chow
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 3.  Anaphylaxis to the carbohydrate side chain alpha-gal.

Authors:  Thomas A E Platts-Mills; Alexander J Schuyler; Anubha Tripathi; Scott P Commins
Journal:  Immunol Allergy Clin North Am       Date:  2015-03-06       Impact factor: 3.479

4.  Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation.

Authors:  Erik Sedlák; Jonas V Schaefer; Jozef Marek; Peter Gimeson; Andreas Plückthun
Journal:  Protein Sci       Date:  2015-06-11       Impact factor: 6.725

5.  Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.

Authors:  Yanli Zhuang; Di Chen; Amarnath Sharma; Zhenhua Xu
Journal:  AAPS J       Date:  2018-10-15       Impact factor: 4.009

6.  Spec-seq unveils transcriptional subpopulations of antibody-secreting cells following influenza vaccination.

Authors:  Karlynn E Neu; Jenna J Guthmiller; Min Huang; Jennifer La; Marcos C Vieira; Kangchon Kim; Nai-Ying Zheng; Mario Cortese; Micah E Tepora; Natalie J Hamel; Karla Thatcher Rojas; Carole Henry; Dustin Shaw; Charles L Dulberger; Bali Pulendran; Sarah Cobey; Aly A Khan; Patrick C Wilson
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

7.  Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.

Authors:  Dennis R Goulet; Adam Zwolak; James A Williams; Mark L Chiu; William M Atkins
Journal:  Proteins       Date:  2019-11-20

8.  Absolute Quantitation of Glycoforms of Two Human IgG Subclasses Using Synthetic Fc Peptides and Glycopeptides.

Authors:  Rini Roy; Evelyn Ang; Emy Komatsu; Ronald Domalaon; Adrien Bosseboeuf; Jean Harb; Sylvie Hermouet; Oleg Krokhin; Frank Schweizer; Hélène Perreault
Journal:  J Am Soc Mass Spectrom       Date:  2018-05-23       Impact factor: 3.109

Review 9.  Opportunities and challenges for TCR mimic antibodies in cancer therapy.

Authors:  Aaron Y Chang; Ron S Gejman; Elliott J Brea; Claire Y Oh; Melissa D Mathias; Dmitry Pankov; Emily Casey; Tao Dao; David A Scheinberg
Journal:  Expert Opin Biol Ther       Date:  2016-04-27       Impact factor: 4.388

10.  Recombinant Proteins and Monoclonal Antibodies.

Authors:  Roy Jefferis
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.